ST2: A novel biomarker for heart failure

Expert Review of Molecular Diagnostics

Volumn 10, Issue 4, 2010, Pages 459-464

  Bhardwaj, Anju ^a   Januzzi Jr , James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

B type natriuretic peptide; Biomarker; Dyspnea; Heart failure; Myocardial infarction; Pro B type natriuretic peptide; Prognosis; ST2

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1 RECEPTOR; NATRIURETIC FACTOR; ST2 PROTEIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; DYSPNEA; ECHOCARDIOGRAPHY; HEART FAILURE; HUMAN; PREDICTION; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; CORONARY DISEASE; DYSPNEA; ECHOCARDIOGRAPHY; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; RECEPTORS, CELL SURFACE; RISK FACTORS; VENTRICULAR REMODELING;

EID: 77952487849     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.25     Document Type: Review

References (28)

1. Lloyd-Jones D, Adams RJ, Brown TM. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (3), 480-486 (2009).
2. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 29 (19), 2388-2442 (2008).
3. Fonarow GC, Corday E. ADHERE Scientific Advisory Committee. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail. Rev. 9 (3), 179-185 (2004).
4. Kakkar R, Lee RT. ST2 and adrenomedullin in heart failure. Heart Fail. Clin. 5 (4), 515-527 (2009).
5. Dieplinger B, Gegenhuber A, Haltmayer M et al. Evaluation of novel biomarkers for the diagnosis of acute destabilized heart failure in patients with shortness of breath. Heart 95 (18), 1508-1513 (2009).
6. Weinberg EO, Shimpo M, De Keulenaer GW et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106 (23), 2961-2966 (2002).
7. McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J. Clin. Invest. 115 (3), 538-546 (2005).
8. Manabe I, Shindo T, Nagai R. Gene Expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ. Res. 91 (12), 1103-1113 (2002).
9. Iwahana H, Yanagisawa K, Ito-Kosaka A et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur. J. Biochem. 264 (2), 397-406 (1999).
10. Sanada S, Hakuno D, Higgins L et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117 (6), 1538-1549 (2007).
11. Barksby HE, Lea SR, Preshaw PM et al. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin. Exp. Immunol. 149 (2), 217-225 (2007).
12. Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor - related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (5), 479-490 (2005).
13. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev. Drug Discov. 7 (10), 827-840 (2008).
14. Feldman AM, Weinberg EO, Ray PE, Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ. Res. 73 (1), 184-192 (1993).
15. Weinberg EO, Shimpo M, Hurwitz S, Tominaga SI, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003 107 (5), 721-726 (2003).
16. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ. Heart Fail. 2 (4), 311-319 (2009).
17. Sweet MJ, Leung BP, Kang D et al. A novel pathway regulating lipopolysaccharideinduced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J. Immunol. 166 (11), 6633-6639 (2001).
18. Januzzi JL, Peacock WF, Maisel AS et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol. 50 (7), 607-613 (2007).
19. Rehman SU, Mueller T, Januzzi JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 52 (18), 1458-1465 (2008).
20. Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL Jr. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin. Chim. Acta 392 (1-2), 41-45 (2008).
21. Mueller T, Dieplinger B, Gegenhuber A et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin. Chem. 54 (4), 752-756 (2008).
22. Boisot S, Beede J, Isakson S et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J. Card. Fail. 14 (9), 732-738 (2008).
23. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 54 (23), 2174-2179 (2009).
24. Shimpo M, Morrow DA, Weinberg EO et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109 (18), 2186-2190 (2004).
25. Sabatine MS, Morrow DA, Higgins LJ et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117 (15), 1936-1944 (2008).
26. Januzzi JL Jr, Camargo CA, Anwaruddin S et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 95 (8), 948-954 (2005).
27. Dieplinger B, Januzzi JL, Steinmair M et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - the Presage ST2 assay. Clin. Chim. Acta 409 (1-2), 33-40 (2009).
28. Martinez-Rumayor A, Camargo CA, Green SM, Baggish AL, O'Donoghue M, Januzzi JL. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am. J. Clin. Pathol. 130 (4), 578-584 (2008).